Early cancer detectionAutoantibody profilingAutoantibodies are increasingly being recognised as a key biomarker class that aids in understanding the interactions between cancer and the immune system.The SeroTag infectious diseases discovery array can enable a better understanding of how SARS-CoV-2 stimulates an immune reaction and can predict responses to vaccines and therapeutics against the virus.Oncimmune’s ImmunoINSIGHTS services are being leveraged by biopharma partners to improve autoimmune disease management and outcomes by providing multiplexed panels and algorithms for the discovery and characterisation of immune activity.The better characterisation of the B-cell antibody repertoire has the potential to provide biomarkers for prediction of clinical response and for the prediction of immune-related adverse events.Professor Jessica HasselOncimmune webinar: The utility of autoantibodies in immuno-oncologyThe better characterisation of the B-cell antibody repertoire has the potential to provide biomarkers for prediction of clinical response and for the prediction of immune-related adverse events.Professor Jessica HasselOncimmune webinar: The utility of autoantibodies in immuno-oncologyWe understand disease through the lens of the human immune system, to enable early detection and better treatment of disease.EventsView allCytokine-Based Cancer Immunotherapies Summit 202130 November - 2 December | Boston, USAEvent—30 Nov 2021Genomics Live 20212 - 4 November | Basel, SwitzerlandEvent—02 Nov 2021Cytokine-Based Cancer Immunotherapies Summit 202130 November - 2 December | Boston, USAEvent—30 Nov 2021Genomics Live 20212 - 4 November | Basel, SwitzerlandEvent—02 Nov 2021Extra TimeEvent—10 Feb 2020Extra Time exhibition10 Feb 2020Our campaign to get approval for a nationwide lung cancer screening programme.EventLatest@OncimmuneECDTSuccessful equity placing of £9.0 millionOpen external linkTweet—25 Mar 2021Dr Annalisa Jenkins in conversation with Adam M Hill. 'Extra Time' podcast.Article—08 Mar 2021@OncimmuneECDTProfiling some of the inspiring women that work at the forefront of the autoantibodies field at Oncimmune #IWDOpen external linkTweet—25 Mar 2021@OncimmuneECDTThe ECLS trial demonstrated a 36% reduction in late-stage diagnosis of #lungcancer with EarlyCDT Lung.Open external linkTweet—18 Jan 2021@OncimmuneECDTOncimmune taking part in "£10 million research collaboration to detect lung cancer earlier"Open external linkTweet—18 Dec 2020@OncimmuneECDT“By backing this pioneering project, we are ensuring that the best therapeutic approaches can be offered to the right patients at the right time.” Business Secretary, Alok SharmaOpen external linkTweet—20 Jul 2020@OncimmuneECDT"Earlier diagnosis is likely to enable more patients to benefit from recent advances in surgery, pharmacological interventions, and radiotherapy." Professor Frank SullivanOpen external linkTweet—18 Dec 2020@OncimmuneECDTProf Ola Winqvist, Professor of Cellular Immunotherapy the Karolinska Institute speaks with Dr Adam M Hill on Extra TimeOpen external linkTweet—05 Jul 2020@OncimmuneECDTOncimmune's collaboration with Roche and University Medical Center Utrecht demonstrates the utility of autoantibodies in methotrexate and tocilizumab treatment selection.Open external linkTweet—18 Dec 2020@OncimmuneECDTProfiling some of the inspiring women that work at the forefront of the autoantibodies field at Oncimmune #IWDOpen external linkTweet—25 Mar 2021@OncimmuneECDT“By backing this pioneering project, we are ensuring that the best therapeutic approaches can be offered to the right patients at the right time.” Business Secretary, Alok SharmaOpen external linkTweet—20 Jul 2020@OncimmuneECDTOncimmune's collaboration with Roche and University Medical Center Utrecht demonstrates the utility of autoantibodies in methotrexate and tocilizumab treatment selection.Open external linkTweet—18 Dec 2020@OncimmuneECDTSuccessful equity placing of £9.0 millionOpen external linkTweet—25 Mar 2021@OncimmuneECDTThe ECLS trial demonstrated a 36% reduction in late-stage diagnosis of #lungcancer with EarlyCDT Lung.Open external linkTweet—18 Jan 2021@OncimmuneECDT"Earlier diagnosis is likely to enable more patients to benefit from recent advances in surgery, pharmacological interventions, and radiotherapy." Professor Frank SullivanOpen external linkTweet—18 Dec 2020Dr Annalisa Jenkins in conversation with Adam M Hill. 'Extra Time' podcast.Article—08 Mar 2021@OncimmuneECDTOncimmune taking part in "£10 million research collaboration to detect lung cancer earlier"Open external linkTweet—18 Dec 2020@OncimmuneECDTProf Ola Winqvist, Professor of Cellular Immunotherapy the Karolinska Institute speaks with Dr Adam M Hill on Extra TimeOpen external linkTweet—05 Jul 2020
